Clinical Trials

Overview

About this study

Neonates who are born prematurely or who experience respiratory problems shortly after birth are at risk for bronchopulmonary dysplasia (BPD).  BPD is the most common pulmonary morbidity in preterm neonates and affects approximately. Babies first diagnosed with BPD receive intense supportive care in the hospital, usually in a neonatal intensive care unit (NICU), where the length of stay can range from several weeks to a few months. Even after leaving the hospital, a baby might require long-term diuretic, bronchodilator or oxygen therapies at home. Although most children with BPD are weaned from supplemental oxygen by the end of their first year, a few with serious cases may need oxygen for through early childhood and beyond. Advances in perinatal care, changes in health care economics and research suggesting a negative impact of prolonged hospitalization on development of the preterm newborn have influenced discharge practices for neonates with BPD. The home environment increasingly has been recognized as the optimal setting for medically stable, technology-assisted neonates to receive the complex and demanding care they require.The goal of the proposed study is to determine whether a newly developed, highly-miniaturized oxygen saturation-monitoring instrument might be of use in the care of neonates with BPD who will transition from the neonatal intensive care unit (NICU) to the home environment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information